News Grower

Independent coverage of AI, startups, and technology.

Ars Technica Apr 16, 2026 at 16:45 Big Tech Rising Hot

RFK Jr. forces FDA to reconsider 12 unproven peptides after 2023 ban

There doesn't seem to be new safety or efficacy data, but Kennedy touts them anyway.

Signal weather

Rising

Momentum is building quickly, so this card is a good early entry point into the topic.

By Beth Mole Original source
RFK Jr. forces FDA to reconsider 12 unproven peptides after 2023 ban

The Food and Drug Administration on Wednesday announced meeting dates for advisors to discuss lifting restrictions on 12 unproven peptides that the agency deemed to pose significant safety risks in 2023. The meetings are scheduled for two days in July, with another in February 2027. The scheduled meetings do not appear to be accompanied by any significant new safety or efficacy data for FDA advisors to discuss. Rather, the FDA is being pushed to ease restrictions on these peptides at the behest of anti-vaccine Health Secretary Robert F. Kennedy Jr., who has described himself as a "big fan" of the unproven drugs. Peptide drugs are simply those made of short chains of amino acids linked by peptide bonds. FDA-approved peptide drugs include insulin for diabetes and GLP-1 drugs for obesity. But online, peptides typically refer to unproven drugs, often given by injection, that are peddled without evidence as treating various conditions, reversing aging, and improving appearance. This category has seen a boom in popularity among wellness influencers, including Kennedy and many of his allies. Read full article Comments

Stay on the signal

Follow RFK Jr. forces FDA to reconsider 12 unproven peptides after 2023 ban

Follow this story beyond a single article: new follow-ups, adjacent sources, and the evolving storyline.

We send a confirmation link first, then only meaningful digests.

Story map

Understand this topic fast

A quick entry into the story: why it matters now, who is involved, and where to go next for context.

Why it matters now

Fresh coverage with immediate momentum.
There are already 6 connected articles in the same storyline to continue from here.
The story keeps orbiting around Ars Technica, Efficacy Data, and FDA, so the entity pages are the fastest way to build context.
Ars Technica already has 4 follow-up stories on the same theme.

Topic constellation

Open the live map for this story

See which entities, story threads, sources, and follow-up articles shape this story right now.

Click nodes to continue

Entity Cluster Article Hub Source

Story timeline

Continue with this story

A short sequence of events and follow-up stories to understand the arc quickly.

Apr 16, 2026 at 18:30 Ars Technica

New Codex features include the ability to use your computer in the background

An in-app browser allows visual feedback while building websites and more.

Apr 16, 2026 at 17:50 Ars Technica

The Ukraine war's deep impact on Metro 2039’s development, story

Upcoming sequel wants to capture a "uniquely Ukrainian perspective" on the post-apocalypse.

Apr 16, 2026 at 17:32 Ars Technica

New undersea cable cutter risks Internet’s backbone

China cable-cutter demo coincides with more sabotage of subsea Internet cables.

Apr 16, 2026 at 16:59 Ars Technica

Gemini can now create personalized AI images by digging around in Google Photos

Google is making it easier to feed your photos into Nano Banana for more personal image generation.

Apr 16, 2026 at 16:45 Ars Technica

RFK Jr. forces FDA to reconsider 12 unproven peptides after 2023 ban

There doesn't seem to be new safety or efficacy data, but Kennedy touts them anyway.

Apr 16, 2026 at 16:23 Ars Technica

First look: Also's upcoming e-bike disconnects the pedals and wheels

The company bets that software can create a distinct—and better—riding experience.

How reliable this looks

Signal and trust for Ars Technica

This source works at a rapid pace: 100% of recent stories land in the hot window, and 0% carry visible search signal.

Trusted

Reliability

92

Freshness

100

Sources in storyline

1

Related articles

More stories that share tags, source, or category context.

More from Ars Technica

Fresh reporting and follow-up coverage from the same newsroom.

Open source page